A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

@article{Jimeno2016AP2,
  title={A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.},
  author={Antonio J. Jimeno and Marshall Roy Posner and Lori J Wirth and Nabil F. Saba and Roger B. Cohen and Elizabeta C Popa and Athanassios Argiris and Kenneth F. Grossmann and Ammar W. Sukari and Dawn M Wilson and Xiaosha Zhang and Jade Sun and Chad E. Glasser and Kenneth M. Attie and Matthew L. Sherman and Susan S Pandya and Jared M Weiss},
  journal={Cancer},
  year={2016},
  volume={122 23},
  pages={3641-3649}
}
BACKGROUND Patients with platinum-refractory, recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) have limited options. Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor β superfamily expressed on activated endothelial cells. Dalantercept is an ALK1 receptor fusion protein that acts as a… CONTINUE READING